Delving into the Latest Updates on Kynurenic acid with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

FIBROSTOP-2, FS-2

Target

GPR35

Action

agonists

Mechanism

GPR35 agonists(G-protein coupled receptor 35 agonists)

Therapeutic Areas

Other Diseases

Active Indication

BurnsCicatrix

Inactive Indication-

Originator Organization

University of British Columbia

Active Organization

University of British Columbia

BirchBioMed, Inc.Startup

Inactive Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC10H7NO3

InChIKeyHCZHHEIFKROPDY-UHFFFAOYSA-N

CAS Registry492-27-3

Sequence Code 553457848

The goal of this study is to see how an ingredient called kynurenic acid (which we named "FS2") affects scar formation in people with burn injuries that need skin graft surgery. A cream with FS2 will be used on both the area where the skin graft was placed and the area where the skin was taken (donor site). The cream will be applied after the skin has healed. This study will help us understand if FS2 is safe and effective for mitigating skin scar formation in burn patients.

Start Date20 May 2025

Sponsor / Collaborator

BirchBioMed, Inc.Startup

[+1]

100 Clinical Results associated with Kynurenic acid

Login to view more data

100 Translational Medicine associated with Kynurenic acid

Login to view more data

100 Patents (Medical) associated with Kynurenic acid

Login to view more data

4,883

Literatures (Medical) associated with Kynurenic acid

01 May 2025·DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY

Serum metabolomics after exercise in ambulatory individuals with cerebral palsy

Article

Author: Dayanidhi, Sudarshan ; Pichika, Rajeswari ; Hanaoka, Chad ; Jayabalan, Prakash

Abstract:

Aim:

To evaluate whether serum metabolomics differ between ambulatory individuals with cerebral palsy (CP) compared with individuals with typical development and whether functional capacity is associated with metabolite abundance.

Method:

Thirty‐eight adolescents and young adults were enrolled (CP: n = 19; typical development: n = 19). After functional capacity testing (10‐meter walk, sit‐to‐stand, and peak knee flexion/extension torques), blood was drawn. Targeted serum metabolomics on hydrophilic metabolites were performed by high‐performance liquid chromatography coupled with high‐resolution and tandem mass spectrometry. Metabolite dimensionality reduction, pathway analysis, fold change, and t‐tests evaluated changes in metabolite abundance. Associations were tested between functional measures and metabolite abundance.

Results:

Individuals with CP had a significant increase in the abundance of essential amino acids, catabolic products of protein metabolism, and tricarboxylic acid cycle substrates, such as valine, tryptophan, kynurenic acid, and pyruvate (p < 0.05). Importantly, the abundance of numerous metabolites was only highly associated with functional capacity in individuals with CP such that greater abundance was associated with greater capacity, but not in those with typical development.

Interpretation:

Our findings show clear increases in serum metabolites in individuals with CP, which are associated with functional capacity for movement. The altered metabolite profile measured after exercise might reflect increased energy production needed for movement. Appropriate nutritional intake during exercise might be needed given increased energy requirements.

01 May 2025·ENVIRONMENTAL RESEARCH

Early life imidacloprid and copper exposure affects the gut microbiome, metabolism, and learning ability of honey bees (Apis mellifera)

Article

Author: Zhao, Chonghui ; Deng, Yi ; Pang, Yantao ; Fang, Richan ; Chen, Yuan ; Guo, Jun ; Chen, Yajuan ; Tang, Qihe ; Zhao, Yazhou ; Li, Xijie ; Li, Dan ; Li, Junjie ; Qian, Kai ; Hou, Mengshang ; Zhang, Jun

The pesticide imidacloprid and the heavy metal copper provide some degree of protection to plants, while at the same time causing varying degrees of damage to bees. However, few studies have investigated the negative effects of imidacloprid and copper exposure on newly emerged bees (young bees), especially when both are present in a mix. In this study, young bees were exposed to sterile sucrose solutions containing imidacloprid (10 μg/L, 100 μg/L), copper (10 mg/L, 50 mg/L), or a mix of both (10 μg/L + 10 mg/L) for 5 days to assess their gut system and behavior, with survival and dietary consumption recorded over 21 days. We found that imidacloprid and copper reduced honeybee survival, dietary intake, and learning ability, decreased gut microbiota diversity, and caused metabolic disruptions. Notably, the mix of imidacloprid and copper had a synergistic negative effect. Correlation analyses revealed that the honeybee gut microbiota influences bee immunity and behavior by regulating metabolic pathways related to ascorbate, tryptophan, and carbohydrates. Our results demonstrate that imidacloprid and copper, either alone or in a mix, alter young bee health through a complex mechanism of toxicity. These findings highlight imidacloprid and copper's negative effects on young honeybees, offering insights for future pesticide and heavy metal impact research.

01 May 2025·Journal of Stroke & Cerebrovascular Diseases

Elevated initial blood kynurenine is associated with increased odds of post-stroke infection

Article

Author: Poisson, Sharon N ; Dylla, Layne ; Sansing, Lauren H ; Monte, Andrew A ; Reisz, Julie A ; Herson, Paco S

OBJECTIVE:

Post-stroke infection is a leading cause of acute ischemic stroke mortality. Tryptophan metabolites can modulate the immune response. This study assesses the association between tryptophan metabolism and post-stroke infection.

METHODS:

Whole blood from the University of Colorado Emergency Medicine Specimen Bank of acute ischemic stroke patients was collected within 72 hours of last known well. Mass spectrometry determined concentrations of tryptophan metabolites. Multivariate logistic regression modeled the association between post-stroke infection within 30 days and metabolite concentrations, controlling for age, sex, NIH stroke scale score, time to sample collection, smoking status, dysphagia, history of chronic kidney or end stage renal disease, and history of diabetes mellitus.

RESULTS:

Of 73 subjects, 21 (28.8 %) developed a post-stroke infection. Those with or without a post-stroke infection had similar concentrations of tryptophan, kynurenic acid and quinolinic acid. Those who developed a post-stroke infection had higher mean concentrations of kynurenine (2.3μM, standard deviation 1.1μM) compared to those who did not develop a post-stroke infection (1.6μM , standard deviation 0.6μM, p = 0.01). The adjusted odds ratio of a post-stroke infection within 30 days was 3.94 (95 % Confidence Interval 1.40 - 11.11) for every 1μM increase in kynurenine concentration.

CONCLUSIONS:

Increasing circulating kynurenine within 72 hours of ischemic stroke onset is associated with increased odds of developing a post-stroke infection within 30 days of emergency department admission. Understanding the causal mechanism of kynurenine promoting post-stroke infection may yield targeted therapeutics that reduce the morbidity and mortality of ischemic stroke.

7

News (Medical) associated with Kynurenic acid

28 Feb 2025

·birchbiomed.com

Rare Disease Day 2025

Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Strategic Partnering Contact Us Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Strategic Partnering Contact Us Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants BirchBioMed Inc., a pioneering clinical-stage Canadian biopharmaceutical company, today (28th February 2025) joins in solidarity with the global community to recognize Rare Disease Day #RareDiseaseDay and underscore the vital importance of raising awareness about the more than 400 million children and adults who live with rare diseases worldwide. Rare Disease Day provides the international community with an opportunity to a focus and commit to addressing the high unmet medical needs of those suffering from one of more than 7,000 rare diseases. We join in renewing our commitment to those individuals and their families and playing an integral role in the efforts of caregivers, healthcare professionals, researchers, clinicians, policymakers, industry representatives, and the public in seeking to find and develop proper, accurate and early diagnosis, as well as innovative, safe and effective treatment options for this vulnerable population in urgent need. At BirchBioMed, our team of world-class scientists, researchers, and business professionals are dedicated to the development of groundbreaking therapies for diseases with high unmet medical needs, including organ fibrosis, scarring, skin disorders, and specific autoimmune conditions including Type-1 Diabetes (T1D). Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs About Us Our Mission Leadership Grants Strategic Partnering News Invest Contact Us BirchBioMed Toronto, ON L7B 1E6 This site is intended for individuals aged 16 and over. © 2024 BirchBioMed™, Inc. All rights reserved Privacy Policy

Cell Therapy

20 Dec 2024

·www.globenewswire.com

Kynexis Announces Positive Topline Results from Phase 1 Study of KYN-5356, a Potential Treatment for Cognitive Impairment Associated with Schizophrenia

KYN-5356, an innovative, first-in-class small molecule inhibitor of KAT-II, a key enzyme in the kynurenine pathway implicated in schizophrenia, was shown to be safe and well-tolerated in the phase 1 study in healthy volunteers Initial data show clear evidence of target engagement and suggestive evidence of cognitive improvement, adding to body of evidence that supports further study of KYN-5356 in patients with cognitive impairment associated with schizophrenia (CIAS), which is among the most debilitating symptoms of the disease Clinical trial in patients anticipated to begin in 2025 Dec. 17, 2024 -- Kynexis, a biotechnology company focused on precision therapeutics for brain diseases, today announced positive topline results from its first-in-human phase 1 clinical trial. The phase 1 study in healthy volunteers evaluated the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of KYN-5356, a first-in-class small molecule inhibitor of KAT-II, being developed for the treatment of cognitive impairment associated with schizophrenia (CIAS). The study also evaluated central pharmacodynamic biomarkers and cognitive performance to determine target engagement in the multiple ascending part. Results show that KYN-5356 was safe and well-tolerated and exhibited excellent pharmacokinetic (PK) properties in both plasma and cerebrospinal fluid (CSF), suggesting appropriate penetration and exposure of KYN-5356 in the central nervous system (CNS). The study also tested exploratory pharmacodynamic (PD) endpoints, where KYN-5356 demonstrated statistically significant improvements in electroencephalography (EEG) activity relevant to cognitive pathways, as well as early, suggestive evidence of cognitive improvement. Findings further showed a dose-dependent reduction of kynurenic acid levels in the CSF, which have been shown to be elevated in people with schizophrenia and are believed to be a key driver of CIAS. “Cognitive impairment is a primary driver of disability for people with schizophrenia and affects most people with the disease. While still early, these data represent a milestone for Kynexis as we advance this potentially first-in-class treatment for cognitive impairment associated with schizophrenia, or CIAS,” said Kees Been, Chief Executive Officer of Kynexis. “As the first KAT-II inhibitor studied in humans, KYN-5356 has demonstrated an excellent safety profile and promising pharmacokinetic data, including evidence of significant brain penetration. The observed dose-dependent reductions in CSF kynurenic acid levels, the effects on EEG activity, and the early evidence of cognitive benefit further validate our precision-medicine approach to targeting the kynurenine pathway for CIAS.” Dr. Jens Wendland, Chief Medical Officer at Kynexis, continued, “All subjects successfully completed the study, and the data provide critical insights into the brain effects of KYN-5356. These findings, including data showing clear target engagement across several biomarker modalities, build on the body of evidence supporting its potential to treat cognitive impairment associated with schizophrenia. We look forward to sharing the full phase 1 results at a scientific conference next year and are now moving swiftly toward initiating our first-in-patient clinical study in 2025.” Kynexis is advancing precision therapeutics for brain diseases by taking a biomarker-based approach to advance a potential treatment for cognitive impairment associated with schizophrenia (CIAS). By harnessing large data to identify and stratify patients based on the underlying causal human biology of the disease, Kynexis is targeting KAT-II, a key enzyme in the kynurenine pathway. The company’s lead candidate, KYN-5356, is a first-in-class small molecule that is potent and highly selective for KAT-II. The Company has a subsidiary in the United States, which is based in Cambridge, Mass. (Kynexis Therapeutics Inc.). Learn more at kynexistx.com and follow us on LinkedIn and X.: The content above comes from the network. if any infringement, please contact us to modify.

Clinical Result

09 Oct 2024

·birchbiomed.com

BirchBioMed Welcomes Hervé Girsault as Chief Business Officer

Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Strategic Partnering Contact Us Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs with KynA About Us Our Mission Leadership Grants Strategic Partnering Contact Us Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Topical Creams Systemic Administration One-Time Delivery of APCs with KynA Our Mission Leadership Grants Page 1 / 2Zoom 100% Disease Areas Topical Scarring & Burns Organ Fibrosis Autoimmune Disorders Wrinkles & Rhytids Our Science Kynurenic Acid MoA Immune Cells Therapy University of British Columbia Products & Pipeline Topical Creams Systemic Administration One-Time Delivery of APCs About Us Our Mission Leadership Grants Strategic Partnering News Invest Contact Us BirchBioMed Toronto, ON L7B 1E6 This site is intended for individuals aged 16 and over. © 2024 BirchBioMed™, Inc. All rights reserved Privacy Policy

Cell Therapy

100 Deals associated with Kynurenic acid

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB11937

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burns	Phase 3	Canada	BirchBioMed, Inc.Startup	20 May 2025
Cicatrix	Phase 3	Canada	BirchBioMed, Inc.Startup	20 May 2025

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


SFN2022	Not Applicable	Cognitive Dysfunction	-	kynurenic acid (KMO SNP rs2275163 CC)	xfevooybty(tpentlnevz) = yxduiwvojz dqtzmvykpb (jthebcximt )	-	14 Nov 2022
SFN2010	Not Applicable	Bipolar Disorder	-	kynurenic acid (Male patients with bipolar disorder)	wikxlhmdgk(znjjpnrnnj) = cmhvqaqxho edkuifuxpq (grkrorsboe )	-	16 Nov 2010
				kynurenic acid (Female patients with bipolar disorder)	wikxlhmdgk(znjjpnrnnj) = flxayzhxzm edkuifuxpq (grkrorsboe )
SFN2008	Not Applicable	Schizophrenia	-	Kynurenine	xviapopofi(ucxkrvnhjh) = napbauwouk uxfarqxvde (vofmakbypn )	-	18 Nov 2008
				Saline	xviapopofi(ucxkrvnhjh) = nyyxmefxic uxfarqxvde (vofmakbypn )
SFN2007	Not Applicable	Achondroplasia	-	S-ESBA	adwucjtsid(vjrfojkmaf) = uzbdkzrixh zmmadmlgzv (inbtgodhrp )	-	05 Nov 2007
SFN2007	Not Applicable	Encephalitis, Tick-Borne	-	kynurenic acid (TBE patients)	dcgdvwyspp(hztnanxdaj) = afxzcyxpfw nhfhfxxxgv (zqhggpqwsj, 1.0)	-	05 Nov 2007
				kynurenic acid (Controls)	dcgdvwyspp(hztnanxdaj) = pwfcnisosp nhfhfxxxgv (zqhggpqwsj, 0.2)
SFN2005	Not Applicable	Schizophrenia	-	kynurenic acid (Schizophrenic patients)	pxbfvcpskh(cqwplcmdss) = fdudvsmchw iivcqbwpie (rziyvqmzjj, 0.1)	-	14 Nov 2005
				kynurenic acid (Controls)	pxbfvcpskh(cqwplcmdss) = bongheywes iivcqbwpie (rziyvqmzjj, 0.06)
SFN2002	Not Applicable	Ischemia	-	kynurenic acid (Transient global ischemia)	wiywcskdnk(tgnzggxoqy) = ahyxbqtcis qhvtiiazzg (hgzghmpfhl ) View more	-	04 Nov 2002
				kynurenic acid (Sham)	wiywcskdnk(tgnzggxoqy) = zfgjkjptdv qhvtiiazzg (hgzghmpfhl ) View more